Answers are grounded in this paper and cite their sources.
Background Polycystic ovary syndrome (PCOS) is commonly accompanied by insulin resistance (IR) and hyperandrogenemia. The serum uric acid to high-density lipoprotein cholesterol ratio (UHR) is an emerging composite metabolic biomarker, yet its relationship with metabolic disturbances in PCOS remains unclear. Objective To evaluate the associations of UHR with IR and hyperandrogenemia in women with PCOS and compare its discrimination with the triglyceride-glucose (TyG) index. Methods This single-center retrospective cross-sectional study included 349 hospitalized women aged 18–45 years with PCOS (2003 Rotterdam criteria, 2012–2025). UHR was calculated as [UA (mg/dL)/HDL-C (mg/dL)]×100%. Associations with IR (HOMA-IR ≥2.69) and hyperandrogenemia were examined using correlation analyses, multivariable logistic models adjusted for age, body mass index, and glomerular filtration rate, and receiver operating characteristic analyses with bootstrap internal validation. Results Higher UHR quartiles were associated with progressively worse metabolic profiles (P for trend <0.05). UHR correlated positively with HOMA-IR (rs=0.449; partial r=0.201 adjusted for age and BMI, both P<0.001). Each 1-SD UHR increase was associated with higher odds of IR after full adjustment (OR = 1.80, 95%CI 1.22~2.66; Q4 vs Q1: OR = 4.12, 95%CI 1.75~9.69). The exploratory hyperandrogenemia analysis showed increased odds in the highest versus lowest quartile in the fully adjusted model (Firth OR = 5.45, 95%CI 1.21~24.53), but no significant association for continuous UHR (OR = 1.29 per 1-SD, 95%CI 0.89~1.87). The AUC of UHR for IR (0.749) was numerically higher than the TyG index (0.691; P = 0.092) and similar to serum UA (0.739); the UHR+TyG combination yielded 0.772 (optimism-corrected 0.769), a small increment over UHR alone. Conclusions Elevated UHR is independently associated with IR and greater metabolic severity in women with PCOS, with discriminative performance not statistically different from the TyG index and a small increment over a basic clinical model. UHR is a simple, inexpensive auxiliary indicator for assessing metabolic severity in PCOS; its clinical utility requires prospective validation.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: